Morphine
Viewing r1 — Apr 27, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Morphine is a naturally-occurring opioid of the morphinan class. It is the principal psychoactive alkaloid in opium and the reference standard against which all other opioid analgesics are measured.[1] Morphine is a full agonist at µ-opioid receptors, producing its effects by suppressing pain transmission and triggering dopamine release in the brain's reward circuitry.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
heroin, oxycodone, hydromorphone +5 moreheroin, oxycodone, hydromorphone, fentanyl, methadone, hydrocodone, codeine, buprenorphine show less
Isolated from opium by Friedrich Sertürner in 1804, morphine was the first alkaloid extracted from any plant — a milestone that launched modern pharmaceutical chemistry.[3][4] It became the backbone of surgical and battlefield analgesia through the 19th and 20th centuries before synthetic opioids progressively displaced it in clinical practice. It remains on the WHO Essential Medicines List and continues to serve as the international reference analgesic.[5]
Subjective effects include profound analgesia, cognitive euphoria, anxiolysis, sedation, and physical warmth. The experience is one of insulation — a heavy, enveloping calm in which pain and emotional distress recede behind a pervasive sense of warmth and contentment that narrows awareness to the immediate present. Nausea, constipation, pupil constriction, and respiratory slowing are characteristic unsought effects.
Morphine produces rapid physical dependence, and dose-dependent respiratory depression is the primary cause of overdose death.[6][7] Tolerance to pain suppression develops faster than tolerance to respiratory depression, so dose escalation progressively narrows the margin between an effective and a fatal dose; tolerance loss after abstinence makes a return to previous doses especially lethal.[8] Over two centuries of clinical use make morphine one of the most thoroughly characterized drugs in pharmacology.[9]
History[edit]
Discovery
Opium — the dried latex of Papaver somniferum — has been used for at least eight millennia, with archaeological evidence of poppy cultivation dating to the sixth millennium BCE in Mesopotamia.[10][4] In 1804, Friedrich Sertürner isolated the compound responsible for opium's effects and named it after Morpheus, the Greek god of dreams. This was the first alkaloid isolated from any plant, establishing the principle that plant extracts contain discrete pharmacologically active molecules.[3][4]
Clinical adoption and scientific impact
Commercial production began when Merck started manufacturing morphine in 1827, and the invention of the hypodermic needle in 1853 enabled injection — dramatically expanding both medical utility and non-medical use.[4] Sir Robert Robinson's structural elucidation earned him the 1947 Nobel Prize in Chemistry, and Marshall Gates achieved the first total synthesis in 1952.[10] The WHO adopted morphine as the Step III reference analgesic in 1986, a position it has held ever since.
Regulation and the modern landscape
The Harrison Narcotic Tax Act of 1914 imposed the first US federal controls on morphine, and the 1961 UN Single Convention on Narcotic Drugs placed it on Schedule I — the most strictly controlled tier — while explicitly recognizing it as medically indispensable. From the 1990s onward, the opioid crisis shifted the landscape: aggressive prescribing of synthetic opioids drove an epidemic of dependence, and fentanyl analogs now dominate illicit overdose deaths in North America. Morphine prescription volumes have declined relative to synthetics, but it retains its WHO reference status and is being studied for emerging indications including chronic breathlessness.[5]
The name morphine derives from Morpheus, the Greek god of dreams — a literary choice by Sertürner that reflected the compound's powerfully sedating and dream-inducing character. During the US Civil War (1861–1865), morphine was used so extensively for battlefield analgesia that an estimated 400,000 soldiers developed opioid dependence, a phenomenon termed "Soldiers' Disease." In 1898, Bayer synthesized heroin (diacetylmorphine) from morphine and marketed it as a "non-addictive" substitute — it was subsequently recognized as more rapidly dependence-forming.[4] Morphine milligram equivalents (MME) remain the standard unit for comparing opioid doses in clinical and regulatory contexts.[9]
Chemistry[edit]
Structural class
Morphine belongs to the morphinan alkaloid family, defined by a tetracyclic 4,5-epoxymorphinan scaffold. This scaffold is the parent structure for a broad range of opioid analgesics including codeine, heroin (diacetylmorphine), hydromorphone, and oxycodone. Semisynthetic derivatives are prepared by modifying the 3-phenol, 6-hydroxyl, or 7,8-double bond positions on morphine's ring system.[10]
Molecular structure
| Molecular formula | C₁₇H₁₉NO₃ |
| Molecular weight | 285.34 g/mol |
Morphine is a pentacyclic alkaloid incorporating a benzofuroisoquinoline ring system fused to a piperidine ring via an oxide bridge. The molecule features a phenolic hydroxyl at C-3 (the site of glucuronidation to morphine-3-glucuronide), an allylic hydroxyl at C-6 (yielding morphine-6-glucuronide), and a tertiary nitrogen bearing a methyl group.[11]
Stereochemistry
Morphine has five stereocenters. Natural (−)-morphine — the levorotatory enantiomer — is the sole pharmacologically active form and the only isomer used in medicine. (+)-Morphine is inactive at opioid receptors.[10][4]
Physical properties and formulations
Morphine free base is a white crystalline powder that is sparingly soluble in water. Pharmaceutical preparations therefore use salt forms — primarily morphine sulfate, morphine hydrochloride, or morphine tartrate — which are roughly 300 times more water-soluble than the free base.[12]
Natural occurrence
Morphine constitutes 8–14% of dried opium latex by weight and is biosynthesized in Papaver somniferum from two molecules of L-tyrosine via the benzylisoquinoline alkaloid pathway. Despite the availability of total synthesis since 1952, commercial production still relies on extraction from poppy straw cultivated primarily in Tasmania, India, and Turkey.[10]
Pharmacology[edit]
Mechanism of action
Morphine is a full agonist at the µ-opioid receptor (μ-opioid), a G-protein-coupled receptor distributed across the entire pain-processing pathway — from peripheral nerve endings through the spinal cord to the brainstem and cortex.[1] It has substantially weaker activity at kappa- and delta-opioid receptors; at therapeutic doses, it is functionally selective for MOR.[13]
When morphine binds MOR, three downstream events follow[2][14]: the enzyme adenylyl cyclase is inhibited, reducing neuronal excitability; potassium channels open, further quieting the neuron; and calcium channels close, cutting the release of pain-signaling chemicals like substance P and glutamate. The combined result is suppressed pain transmission at every level of the nervous system.
MOR activation in the brain's reward regions — the nucleus accumbens and ventral tegmental area — drives dopamine release, producing euphoria and reinforcement. Morphine is also a substrate of the P-glycoprotein efflux pump at the blood–brain barrier, which limits how much drug reaches the brain compared to more lipophilic opioids like fentanyl.[15]
Pharmacokinetics
Oral bioavailability of immediate-release morphine is 20–40%, limited by extensive first-pass metabolism in the liver and gut wall.[16][17] The oral-to-injection potency ratio is approximately 1:3 — meaning an oral dose must be roughly three times larger than an injected dose to achieve the same effect.[17]
Morphine is metabolized primarily by the liver enzyme UGT2B7, producing two glucuronide metabolites.[18][19] Morphine-3-glucuronide (M3G) accounts for roughly 75–80% of metabolic output and is inactive at opioid receptors, though at high concentrations it may paradoxically increase pain sensitivity. Morphine-6-glucuronide (M6G) comprises 15–20% and is an active opioid agonist significantly more potent than morphine itself — it accumulates in people with impaired kidney function, producing prolonged and intensified effects.[17][20]
Genetic variation in UGT2B7 alters the ratio of M3G to M6G, contributing to the wide differences in morphine response between individuals.[18] A common variant in the opioid receptor gene (OPRM1 A118G) may also affect how strongly M6G activates the receptor.[20]
The half-life averages 2–4 hours, though published values range widely (0.7–7.8 hours) due to individual variability.[16] Kidney impairment causes M6G accumulation and elevated toxicity risk;[17] liver disease increases oral bioavailability by reducing first-pass metabolism.[16]
Neuroscience[edit]
Where it acts
Morphine's analgesic and euphoric effects arise from two overlapping circuits. In the periaqueductal gray and brainstem, μ-opioid activation engages descending inhibitory pathways that suppress pain signals at the spinal cord — the primary mechanism of opioid pain suppression.[21] In the ventral tegmental area, morphine silences inhibitory interneurons, releasing a surge of dopamine into the nucleus accumbens — the brain's core reward circuit, shared across substances of abuse.[2] The brainstem's respiratory rhythm generator (pre-Bötzinger complex) is also MOR-rich, which is why respiratory depression tracks dose so closely.[6][22]
Tolerance and dependence at the neural level
Chronic morphine exposure triggers a compensatory upregulation of the cAMP signaling system that normally sits downstream of MOR, effectively opposing the drug's effects and requiring higher doses.[8] At the receptor itself, morphine is unusually poor at triggering receptor internalization — meaning desensitized receptors linger on the cell surface instead of being recycled and refreshed.[23] Morphine also displaces the brain's own opioid peptides (β-endorphins, enkephalins, dynorphins); chronic exposure downregulates endogenous opioid tone, contributing to the persistent low mood and heightened pain sensitivity that characterize withdrawal and protracted abstinence.[2]
Several major questions remain unresolved. Whether morphine's pattern of receptor activation (favoring G-protein signaling over β-arrestin recruitment) meaningfully separates its respiratory depression from its analgesia is actively debated — the biased agonism hypothesis remains contested.[14] The role of spinal glial cells in driving morphine tolerance independently of neuronal mechanisms is a growing area of investigation.[24] And the timeline for full recovery of endogenous opioid function after chronic exposure — and whether incomplete recovery explains protracted withdrawal — remains unknown.
Subjective Effects[edit]
Morphine's experiential signature is a pervasive physical warmth and emotional insulation that sets it apart from non-opioid analgesics. At lower doses the effect is a gentle lifting of discomfort and a quiet, diffuse contentment; at higher doses it deepens into heavy sedation and a near-total withdrawal from external concern. Set and setting powerfully shape the affective character — the same dose can feel like clinical relief in a hospital bed and something qualitatively different in a non-medical context, reflecting the dual role of µ-opioid receptors in both pain suppression and reward.
Compared to oxycodone, morphine produces more pronounced sedation and histamine-mediated flushing and itching at equivalent analgesic doses. Relative to fentanyl, morphine's slower onset and longer duration create a less abrupt experiential arc, with a wider window between the first subjective effects and the onset of dangerous respiratory depression.
Effect Grid
At common oral doses (15–30 mg), the full opioid experience emerges: pronounced cognitive euphoria, significant anxiety suppression, and a deep sense of physical and emotional well-being. Pain is substantially suppressed. Thought deceleration is noticeable — mental activity slows, and a pleasant sense of unconcern replaces ordinary worry. A compulsive redosing urge may arise as the peak fades.
Sedation becomes moderate to pronounced. Miosis is marked. Nausea and vomiting may occur, especially in opioid-naive users. Constipation, urinary retention, and pruritus are common. Respiratory rate decreases measurably.
Significant functional impairment — driving and operating machinery are unsafe. Sleep onset is facilitated, and vivid dreaming may occur.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual acuity suppression · Visual haze / noise · Dreaming enhancement · Visual processing suppression · Internal hallucinations · Auditory hallucinations · External hallucinations
Internal hallucinations · Auditory hallucinations · External hallucinations
Pain suppression · Tactile euphoria · Spontaneous body sensations · Bodily heaviness · Body high · Muscle relaxation · Sexual arousal suppression · Nausea · Appetite suppression · Breathing alteration · Dizziness · Physical fatigue · Dry mouth · Excessive sweating · Temperature dysregulation · Tingling / electric sensations · Vomiting · Abnormal heartbeat · Heart rate perception changes · Nasal congestion · Pain enhancement · Nystagmus (eye wobbles) · Involuntary body movements · Bodily dissociation
Bodily heaviness · Body high · Muscle relaxation · Sexual arousal suppression · Nausea · Appetite suppression · Breathing alteration · Dizziness · Physical fatigue · Dry mouth · Excessive sweating · Tingling / electric sensations · Vomiting · Abnormal heartbeat · Heart rate perception changes · Nasal congestion · Pain enhancement · Nystagmus (eye wobbles) · Involuntary body movements · Bodily dissociation
Cognitive fatigue · Focus suppression · Information processing suppression · Analysis suppression · Memory fragmentation · Memory suppression · Motivation suppression · Confusion · Language suppression · Thought disorganization · Cognitive dysphoria · Amnesia
Analysis suppression · Memory fragmentation · Memory suppression · Motivation suppression · Confusion · Language suppression · Thought disorganization · Cognitive dysphoria
Anhedonia · Dysphoria
Social disconnection · Depersonalization · Derealization · Cognitive disconnection
Timeline
First perceptible effects emerge as a subtle warmth in the abdomen and a mild shift in emotional tone. Pain perception begins to recede.
Warmth spreads through the body. Mood elevation, mild euphoria, and anxiolysis develop progressively. Pupil constriction and slight nausea may appear.
Maximum analgesic and euphoric effects. Pronounced sedation, complete pain suppression, and deep contentment. Respiratory rate is measurably reduced.
Effects remain noticeable but intensity gradually declines. Sedation and warmth persist. Constipation and urinary retention may become apparent.
Analgesic and euphoric effects fade. Mild residual sedation and physical comfort remain. Some individuals experience a compulsive urge to redose as effects wane.
Residual drowsiness, mild constipation, and slight mood elevation may persist for several hours. Cognitive and psychomotor impairment can outlast subjective effects.
⚠ Do not drive or operate machinery for at least 6 hours after the last dose, or longer if any sedation persists.
Safety[edit]
- Acute toxicity
- Critical
- Chronic toxicity
- High
- Withdrawal
- Severe
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- heroin · oxycodone · hydromorphone
Toxicity
Morphine's primary acute danger is dose-dependent respiratory depression: the drug progressively slows breathing by acting on the brainstem's respiratory rhythm generator, leading to oxygen deprivation, coma, and death.[6][22] The classic opioid overdose presentation is pinpoint pupils, slowed or stopped breathing, and unconsciousness. No published human lethal dose exists — fatal doses are highly variable and critically dependent on tolerance status.
In opioid-naïve individuals, life-threatening respiratory depression can occur at oral doses as low as 60 mg or intravenous doses as low as 30 mg.safety citation needed Tolerance loss after periods of abstinence (incarceration, hospitalization, completion of treatment) is a primary driver of fatal overdose — returning to a previously tolerated dose after a break can be lethal.[7][25]
All morphine effects, including respiratory depression, are reversed by the opioid antagonist naloxone (0.4–2.0 mg intravenous, intramuscular, or intranasal, repeated every 2–3 minutes as needed). Multiple doses may be required because morphine outlasts naloxone in the body.[26]
Morphine-6-glucuronide accumulation
Morphine's active metabolite M6G is cleared by the kidneys. In people with impaired kidney function, M6G accumulates and produces prolonged opioid effects — including life-threatening respiratory depression — even after morphine itself has been eliminated.[17][20]
Histamine release
Unlike fentanyl, morphine triggers direct histamine release from mast cells, producing flushing, itching, hives, and low blood pressure. This is a pharmacological effect, not an allergic reaction, though it is frequently misidentified as allergy in clinical settings.
Opioid-induced hyperalgesia
Paradoxically, chronic morphine use can increase pain sensitivity — a phenomenon called opioid-induced pain enhancement (OIH). OIH produces diffuse pain unrelated to the original pain site and characteristically worsens with dose increases, distinguishing it from simple tolerance.[24][21]
Organ effects with chronic use
- Respiratory: Primary acute toxicity target; dose-dependent depression of breathing rate and depth.
- Endocrine: chronic use suppresses sex hormones, producing reduced libido, sexual dysfunction, and menstrual irregularities.
- Gastrointestinal: constipation, nausea, vomiting, and slowed stomach emptying. Notably, tolerance does not develop to constipation with continued use.
- Cardiovascular: Histamine-mediated blood vessel dilation and low blood pressure; dizziness on standing.
Psychological risks
Morphine produces a strong compulsive redosing urge driven by its action on the brain's reward circuitry.[27] Chronic use suppresses the brain's own opioid system; stopping produces persistent low mood, emotional numbness, and an anhedonia that can last weeks to months beyond acute withdrawal.
Chronic opioid use is also associated with impairments in attention, memory, and decision-making, though how fully these reverse after cessation remains debated.
Tolerance and dependence
Physical dependence develops within days to weeks of regular use. The acute withdrawal syndrome includes sweating, goosebumps, watering eyes, runny nose, rapid heartbeat, nausea, vomiting, diarrhea, abdominal cramps, muscle aches, restless legs, anxiety, irritability, insomnia, and intense dysphoria.
Withdrawal severity peaks 24–72 hours after the last dose and largely resolves within 5–10 days. A protracted abstinence syndrome — low mood, disrupted sleep, and persistent craving — may continue for weeks to months.[28]
Tolerance develops through compensatory upregulation of the cell's signaling machinery and poor recycling of desensitized receptors.[8][23] Full cross-tolerance exists with all other µ-opioid agonists: heroin, oxycodone, hydromorphone, Fentanyl, methadone, and buprenorphine (partial).
Drug interactions
The dominant danger with morphine is pharmacodynamic synergy with other depressants — any substance that slows breathing or consciousness multiplies morphine's lethal risk.
CNS depressant synergy
Alcohol synergistically increases morphine-induced respiratory depression and is consistently found as a co-intoxicant in postmortem opioid cases.[7]
Benzodiazepines combined with morphine produce synergistic respiratory depression. The CDC prescribing guideline specifically warns against concurrent prescribing.[9]
GHB/GBL combined with morphine produce synergistic respiratory depression through additive depressant mechanisms.citation needed
Pharmacokinetic interactions
Cannabis (THC/CBD): Both THC and CBD inhibit the enzyme responsible for morphine's metabolism (UGT2B7) in vitro. Modeling predicts clinically significant increases in morphine and M6G blood levels with concurrent cannabis use.[19]
Context-dependent interactions
Ketamine at low doses is used clinically alongside morphine as an opioid-sparing strategy without elevated mortality. At higher recreational doses, combined depressant effects increase sedation and respiratory depression risk.
Tramadol adds to morphine's respiratory depression through shared µ-opioid agonism. Risk is elevated at high doses but the combination is used in clinical settings.[29]
MAOIs used concurrently with morphine carry risk of severe respiratory depression.safety citation needed
Contraindications
Absolute
- Severe respiratory depression or acute severe asthma (outside monitored settings): morphine will worsen breathing failure.
- Known true allergy to morphine or morphinan opioids (distinct from histamine release, which is not an allergy).
- Bowel obstruction: morphine slows gut motility and will worsen obstruction.
Relative
- Kidney impairment: M6G accumulation produces prolonged and intensified opioid effects.[17]
- Liver disease: reduced first-pass metabolism increases oral bioavailability.[16]
- Raised pressure inside the skull: morphine may increase intracranial pressure via reduced breathing and carbon dioxide buildup.
- Concurrent MAOI therapy: risk of severe respiratory depression.
- Pregnancy and breastfeeding: morphine crosses the placenta and enters breast milk; chronic maternal use can cause neonatal withdrawal.
Harm Reduction[edit]
Forms & Identification
Morphine circulates in pharmaceutical forms (tablets, capsules, oral solutions, injectable ampoules) and occasionally as diverted hospital-grade powder. The structured module above shows common forms, reagent results, and adulterant data. Because morphine is less commonly encountered in unregulated powder form than heroin or fentanyl, many users interact with identifiable pharmaceutical products — but diverted medications can be counterfeit, and any unverified tablet or powder should be treated as unknown composition until tested.
Fentanyl test strips are the single most important precaution for any opioid acquired outside a pharmacy. Fentanyl contamination of the unregulated opioid supply is widespread and a microgram-level contaminant can be lethal. Testing does not guarantee safety but meaningfully reduces the single deadliest risk.
Guidelines
- Test every dose from an unverified source with fentanyl test strips at minimum.
- Start low. If tolerance status is uncertain — especially after any period of abstinence — begin with a fraction of the previously tolerated dose. Tolerance loss is the single most dangerous variable in opioid use.
- Never use alone. Have a sober companion present, or at minimum use a phone-based overdose detection service.
- Keep naloxone accessible. Naloxone should be within arm's reach of any companion present. It is available without prescription in most US states and many other jurisdictions.
- Avoid mixing with other depressants. Alcohol, benzodiazepines, and other sedatives synergistically increase respiratory depression — this combination drives the majority of polydrug opioid deaths.
- Wait before redosing. Oral morphine takes 30–90 minutes to reach full effect. Redosing before peak increases the risk of accidentally stacking to a dangerous level.
- Plan for impaired judgment. Morphine blunts risk perception and decision-making. Decisions about redosing should be made before use, not during.
Set & Setting
Morphine's respiratory-depressant effects mean the physical environment matters as much as the psychological one. Using alone is the primary modifiable risk factor for fatal overdose — most opioid deaths occur when no one is present to administer naloxone or call for help.
Avoid using in positions where airway obstruction is likely if consciousness is lost (face-down on soft surfaces). A sober companion who knows how to recognize overdose signs and administer naloxone substantially reduces fatality risk.
Aftercare & integration. After opioid use, physical recovery centers on hydration, nutrition, and sleep. Constipation may persist for days after a single use; adequate fluid and fiber intake help. Nausea typically resolves within hours but can recur with movement.
For people using morphine to manage chronic pain, distinguishing between undertreated pain, tolerance, and opioid-induced pain enhancement requires honest self-assessment and medical guidance. If pain is worsening despite dose increases, OIH should be considered.
Psychological aftercare is most relevant for people who recognize a pattern of non-medical use. The characteristic emotional insulation morphine provides can mask distress that returns — amplified — once the drug wears off. Acknowledging this rebound effect and having support structures in place reduces the pull toward compulsive redosing.
Recovery & Support
Morphine dependence is a medical condition with effective, evidence-based treatments. Opioid agonist therapy (OAT) with methadone or buprenorphine is the gold-standard intervention: it stabilizes opioid receptor activity, eliminates withdrawal, reduces craving, and is associated with large reductions in overdose death.
Abrupt cessation without medical support carries high relapse risk, and relapse after tolerance loss is the highest-risk period for fatal overdose. Medically managed tapering or transition to OAT is strongly preferred.
Support resources include SAMHSA's National Helpline (1-800-662-4357), local harm reduction organizations that provide naloxone and drug checking, mutual aid groups (NA, SMART Recovery), and peer recovery specialists. The decision to seek help is not an endpoint — it is the beginning of an ongoing process, and multiple attempts are the norm, not the exception.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: breathing that is very slow (fewer than 8 breaths per minute), shallow, or stopped; blue or grey lips and fingertips; gurgling or snoring sounds from an unconscious person; unresponsiveness to shouting or sternal rub. These signs distinguish dangerous overdose from heavy sedation.
Immediate steps:
- Administer naloxone immediately: 0.4–2.0 mg intranasal or intramuscular.
- Call emergency services.
- If no response after 2–3 minutes, give a second dose of naloxone.
- Place the person in the recovery position (on their side, mouth angled downward) to prevent choking.
- Stay with them. Do not leave — naloxone wears off in 60–90 minutes, and morphine may still be active, causing re-sedation.
- Do not put them in a bath or try to "walk them awake."
What to tell the dispatcher: "Possible opioid overdose. The person is not breathing / breathing very slowly. I have given naloxone." Provide the substance if known, approximate amount, time of use, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agent: Naloxone is a complete opioid antagonist that reverses all morphine effects. Multiple doses may be needed because morphine outlasts naloxone in the body. After naloxone administration, the person must be monitored for at least 2 hours for re-sedation.
Legal Status[edit]
Morphine is internationally controlled as a substance with high abuse potential and recognized medical necessity. The UN Single Convention on Narcotic Drugs (1961) lists morphine on Schedule I — the most strictly controlled tier — while explicitly designating it as indispensable for medical use, a dual classification shared by the opioid analgesics.[30]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule II (Controlled Substances Act, 1970) | High abuse potential with accepted medical use. Prescription required; no refills without new prescription. CDC guideline establishes 90 MME/day or above as high-risk threshold[9] |
| United Kingdom | Class A / Schedule 2 (Misuse of Drugs Act 1971) | Maximum penalties for unlawful supply: life imprisonment. Schedule 2 permits medical prescription with full audit trail |
| Canada | Schedule I (Controlled Drugs and Substances Act, 1996) | Highest control tier. Medical prescription permitted with strict record-keeping |
| Australia | Schedule 8 (Controlled Drug) | State and territory Poisons Acts. Requires authority prescription in most states |
| International | Schedule I (UN Single Convention on Narcotic Drugs, 1961) | Most strictly controlled tier. Explicitly recognized as medically indispensable. INCB monitors global production and trade |
US Schedule II and UN Schedule I are not equivalent classifications despite sharing the "Schedule I" label in the UN system. US Schedule I denotes no accepted medical use (e.g., heroin in the US), whereas UN Schedule I allows medical use under strict controls. This terminological distinction is a frequent source of confusion in policy discussions.
No changes to morphine's scheduling in any major jurisdiction have been identified as of April 2026.
references
- [1]
- [2] ^abcdCorder G, Castro DC, Bruchas MR, Scherrer G (2018) Endogenous and Exogenous Opioids in Pain — Annual Review of Neuroscience doi:10.1146/annurev-neuro-080317-061522
- [3] ^abMarton J, Cumming P, Rice KC, Linders JTM (2025) Morphinan Alkaloids and Their Transformations: A Historical Perspective of a Century of Opioid Research in Hungary — International Journal of Molecular Sciences doi:10.3390/ijms26062736
- [4]
- [5] ^abJohnson MJ, Williams B, Keerie C, Tuck S, Hart S, Bajwah S, et al. (2025) Morphine for chronic breathlessness (MABEL) in the UK: a multi-site, parallel-group, dose titration, double-blind, randomised, placebo-controlled trial — The Lancet Respiratory Medicine doi:10.1016/s2213-2600(25)00205-x
- [6] ^abcHill R, Santhakumar R, Dewey W, Kelly E, Henderson G (2020) Fentanyl depression of respiration: Comparison with heroin and morphine — British Journal of Pharmacology doi:10.1111/bph.14860